In May 2026, Japan’s CellFiber announced progress on its collaboration with Taiwan’s Locus Biosciences (樂迦再生科技): Locus had adopted CellFiber’s cell culture technology to establish a GMP-compliant large-scale manufacturing process for umbilical cord-derived mesenchymal stem cells, and with the formal opening of their automated facility in Zhubei, the process achieved full automation. CellFiber company announcement
There is one aspect of collaborations like this that I want to look at more closely: when technology is handed to another team for production, what has to be transferred alongside the equipment and operating documents?
Pages 143–144 of the 2026 Biotechnology Industry White Paper survey domestic companies’ manufacturing and CDMO positioning, while page 212 describes the direction of the Biomedical Technology and Device Research Laboratories in building cell culture process platforms and functional verification systems. All of this work converges on the same task: confirming that each batch of product meets predetermined quality requirements.
Developing and manufacturing cell products requires understanding how raw materials and process conditions affect product characteristics. The FDA’s research on cell therapy product characterization also identifies donor variability, culture conditions, and related quality assessments as active areas of study. FDA Cell Therapy Product Characterization Research
During scale-up, teams must decide which conditions are worth monitoring, at what point deviations require action, and how to keep records detailed enough that someone who was not present can understand what actually happened.
What Potency Testing Measures
Cell count and viability provide information about product condition. Assessing the biological activity associated with a product’s intended mechanism, however, involves potency testing.
The FDA’s 2011 guidance on potency tests for cellular and gene therapy products emphasizes that testing must be developed in light of each product’s specific characteristics. There is no universal test or acceptance criterion that applies across all products. FDA Potency Testing Guidance
Teams must first understand the function the product is intended to retain, then build a meaningful measurement method around it. Being able to generate a number and having that number actually reflect the function you care about are two different things. Evidence is needed to connect them.
Potency is also not the same as clinical efficacy for the patient. The former is part of product quality assessment; the latter requires its own clinical evidence. Conflating the two places laboratory results under pressure to answer questions they are not yet equipped to answer.
Transferring the test method alone is not enough. The receiving team needs to understand why that particular item is being tested and what a shift in values might mean. If that judgment stays only with the originating team, the technology transfer is not finished.
After a Process Change, Which Data Still Applies?
Scale-up may involve changing equipment, site, or operating procedures. If those changes affect product characteristics, comparability before and after the change must be assessed. Sharing a product name is not a sufficient basis for assuming that existing evidence still applies.
The FDA’s 2023 draft guidance on manufacturing changes and comparability for cell and gene therapy products discusses how to evaluate the impact of manufacturing changes. As of September 2026, this document remains a draft, but it is a useful window into how regulators frame the assessment of manufacturing changes. FDA Draft Guidance on Manufacturing Changes and Comparability
Comparability does not require every measurement to be identical before and after. It requires appropriate data to evaluate differences and their significance. How far that assessment needs to go depends on the product, the nature of the change, the stage of development, and the applicable regulatory requirements.
The data needed for comparison should ideally be prepared before the change is made. If the original process left no adequate baseline, searching for comparative data after new equipment is already running narrows your options considerably. By final release testing, there may be no way to recover data that was never collected in the first place.
After Handing Off to Another Team
A CDMO, or contract development and manufacturing organization, can take on different portions of process development, analytics, and production. The actual division of work depends on the contract and the organization’s capabilities. Using the same term does not mean every company offers the same services.
Operating steps can be written down. But certain judgments also need to be communicated: which deviations are acceptable, how to investigate when something goes wrong, and who to notify when a key starting material changes. Both parties need to share a common understanding of these things.
Beyond price, the deliverability of data is worth addressing in the contract. Which raw records the sponsor can access, how analytical methods will be transferred, and whether necessary data can be taken to a new partner in the future all affect long-term flexibility.
Once a product leaves the factory, it still needs to be stored, transported, and received. For cell products, those conditions belong inside product development and quality assessment. Specific acceptable time windows, temperature ranges, and handling procedures must be grounded in validation data for each individual product.
The clinical site also needs to know how to receive the product. If the manufacturing side and the end user have different understandings of preparation time, documentation, or handling requirements, delivery can run into problems even after the factory has finished production. These handoff scenarios are worth rehearsing before the supply chain is finalized.
Progress on scale-up is visible in facilities and production numbers. What is harder to read from an announcement is whether, when a new team encounters an out-of-specification batch, they can trace the cause and manufacture the next batch correctly. That is the manufacturing capability I want to keep watching.
Sources: 2026 Biotechnology Industry White Paper, Industrial Development Administration, Ministry of Economic Affairs, August 2026, printed pages 143–144, 212. FDA documents and company announcements are linked in the text above. Company progress is described as reported in public announcements; the questions about evaluating manufacturing partnerships reflect the author’s own analysis.
- Keep a baseline
Retain the original process conditions, test methods and records.
- Assess process changes
Evaluate the effects of changes in equipment, site or operations.
- Complete the handover
Equip the receiving team to interpret results, handle deviations and meet delivery conditions.
A guide to this article’s manufacturing and technology-transfer questions. Potency is part of quality assessment; it is not the same as clinical efficacy in patients.


💬 Comments
Loading...